Five papers that should be on your radar — May 17, 2026

Five Phase 3 trials this week, across autoimmune disease, stroke, antimicrobial resistance, lymphoma, and obesity pharmacotherapy. All five changed — or are about to change — how clinicians manage patients in those areas.

Ranking methodology: papers indexed May 14–17, 2026 on PubMed. Ranked by (1) journal impact factor (NEJM ~176, The Lancet ~169, BMJ ~107), (2) early citation momentum from Google Scholar, (3) clinical significance and breadth of practice impact, (4) study design quality. Because all papers are under 72 hours old, citation counts are near zero; journal impact factor and clinical significance are the primary ranking drivers this week.

1. Brepocitinib in dermatomyositis (VALOR) — first oral TYK2-JAK1 inhibitor clears Phase 3

Journal: New England Journal of Medicine, Vol 394 No 19, pp 1883–1893 (published May 14, 2026) Impact tier: IF ~176 · First quartile Citation momentum: 7 citations in 3 days, including a Nature Reviews Rheumatology highlight Peer-review status: Published in peer-reviewed journal (NEJM); Phase 3 RCT

Study design

VALOR was a double-blind, placebo-controlled Phase 3 RCT. Investigators enrolled 241 adults with dermatomyositis who had failed at least one prior therapy. Participants were randomized 1:1:1 to brepocitinib 30 mg, brepocitinib 15 mg, or placebo for 52 weeks.

Brepocitinib (Priovant Therapeutics) is a first-in-class oral selective TYK2 (tyrosine kinase 2) and JAK1 (Janus kinase 1) inhibitor. Dermatomyositis is a rare inflammatory muscle disease with skin involvement; no drug is currently approved for it.

Key findings

Primary endpoint was the Total Improvement Score (TIS, 0–100 scale) at week 52:

Arm	TIS	Difference vs. placebo (95% CI)	P-value
Brepocitinib 30 mg	46.5	+15.3 (6.7 to 24.0)	<0.001
Brepocitinib 15 mg	37.5	+6.3 (−2.4 to 14.9)	Not significant
Placebo	31.2	—	—

The 30 mg dose was superior to placebo on all 9 pre-specified key secondary endpoints, covering skin disease activity, glucocorticoid tapering, and functional disability. Improvements appeared as early as week 4.

Safety: serious infections occurred in 10% of the 30 mg group vs. 1% of the placebo group. No deaths.

Clinical implication

Brepocitinib 30 mg provides the first Phase 3 evidence of efficacy in treatment-resistant dermatomyositis. The 10% serious infection rate requires careful patient selection and monitoring — this is not a benign safety profile — but for a disease with no approved therapies and limited immunosuppressive options, the benefit-risk calculus is likely favorable in refractory cases.

Lead author: Ruth Ann Vleugels, MD, MPH — Mass General Brigham / Harvard Medical School, Boston, MA 1

Funding: Priovant Therapeutics (industry)

2. Endovascular thrombectomy for medium-vessel-occlusion stroke (ORIENTAL-MeVO)

Journal: New England Journal of Medicine, Vol 394 No 19, pp 1894–1904 (published May 14, 2026) Impact tier: IF ~176 · First quartile Citation momentum: 1 citation; accompanied by an editorial by Ospel & Hill in the same NEJM issue Peer-review status: Published in peer-reviewed journal (NEJM); Phase 3 RCT

Study design

Open-label RCT at 48 centers in China. Investigators enrolled 563 patients (280 thrombectomy, 283 control) with medium-vessel-occlusion (MeVO) stroke — defined as occlusion of M2/M3 middle cerebral artery segments or equivalent vessels, distinguished from large-vessel occlusion (LVO) by smaller caliber. Median age 71, median NIHSS (National Institutes of Health Stroke Scale) score 10. Trial ID: NCT06146790. Funded by the National Natural Science Foundation of China.

The primary endpoint was switched from modified Rankin Scale (mRS) shift to functional independence (mRS 0–2 at 90 days) mid-trial after the proportional-odds assumption was found to be violated — a pre-specified contingency, but one worth flagging as it affects direct comparison with prior MeVO trials.

Key findings

Functional independence at 90 days: 58.6% (thrombectomy) vs. 46.6% (control); adjusted rate ratio 1.24 (95% CI 1.07–1.44, P=0.004). Absolute benefit: +12 percentage points.

Safety: symptomatic intracranial hemorrhage (sICH) 4.7% vs. 2.2%. 90-day mortality 11.1% vs. 10.2% (no significant difference). 2

Clinical implication

Thrombectomy should be considered for carefully selected MeVO patients with NIHSS ≥6 and presentation within 24 hours. The tradeoff: a 12-point gain in functional independence against a roughly doubled sICH rate (4.7% vs. 2.2%). The mortality curves were parallel, suggesting the hemorrhagic complications are occurring but not translating into excess death in this population. Generalizing from a single-country, 48-center Chinese cohort to other health systems warrants the usual caveats around operator volume and patient selection.

Lead author: Wei Hu, MD — First Affiliated Hospital, University of Science and Technology of China, Hefei, Anhui

Funding: National Natural Science Foundation of China (Grant 82471311); public funding

3. Cefepime-nacubactam for complicated UTI (Integral-1) — superior to imipenem-cilastatin

Journal: The Lancet, Vol 407 No 10542, pp 1929–1940 (published May 16, 2026) Impact tier: IF ~169 · First quartile Citation momentum: 2 citations; companion Lancet commentary on β-lactam/β-lactamase inhibitor strategies Peer-review status: Published in peer-reviewed journal (The Lancet); Phase 3 RCT

Study design

Multicenter, double-blind, Phase 3 RCT across 79 sites in 9 countries. Enrolled 431 patients in the microbiological modified intent-to-treat (mITT) population with complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis. Randomized 2:1:1 to cefepime-nacubactam (n=214), aztreonam-nacubactam (n=112), or imipenem-cilastatin (n=105), administered intravenously every 8 hours for 5–14 days. Trial ID: NCT05887908.

Nacubactam is a novel diazabicyclooctane β-lactamase inhibitor — a structural class distinct from existing agents like avibactam and tazobactam — that inhibits serine β-lactamases including extended-spectrum β-lactamases (ESBLs) and certain carbapenemases. 3

Key findings

Primary composite endpoint (clinical + microbiological success at test of cure):

Arm	Success rate	Difference vs. imipenem-cilastatin (95% CI)	Verdict
Cefepime-nacubactam	82%	+21.3% (10.9 to 32.0)	Non-inferior and superior
Aztreonam-nacubactam	72%	+11.4% (−1.2 to 23.7)	Non-inferior
Imipenem-cilastatin	61%	—	Reference

Treatment-emergent adverse events: 33% (cefepime-nacubactam), 30% (aztreonam-nacubactam), 43% (imipenem-cilastatin). No treatment-related deaths in any arm.

Clinical implication

Cefepime-nacubactam is the first agent in this class to demonstrate superiority over a carbapenem for cUTI. For clinicians managing patients with ESBL-producing or other resistant Gram-negative organisms, this offers an intravenous option that outperforms the current carbapenem standard without the resistance-escalation pressure that heavy carbapenem use generates. Whether the superiority finding holds in broader patient populations — including those with bacteremia — requires further trials, but the safety signal is favorable.

Lead author: Satoshi Takahashi — Sapporo Medical University School of Medicine, Sapporo, Japan Corresponding author: Hiroshige Mikamo — Aichi Medical University Hospital, Nagakute, Japan

Funding: Meiji Seika Pharma + Japan Agency for Medical Research and Development (AMED); mixed industry-public funding

4. Ibrutinib without transplant for younger MCL patients (TRIANGLE, 4.5-year follow-up)

Journal: The Lancet, Vol 407 No 10542, pp 1953–1967 (published May 16, 2026) Impact tier: IF ~169 · First quartile Citation momentum: The 2024 TRIANGLE publication accrued 187 citations; this 4.5-year follow-up is the confirmatory data set Peer-review status: Published in peer-reviewed journal (The Lancet); Phase 3 RCT

Study design

Three-arm, Phase 3, open-label superiority RCT across 165 centers in 13 European countries plus Israel. Enrolled 870 patients aged 18–65 with previously untreated stage II–IV mantle cell lymphoma (MCL, an aggressive B-cell non-Hodgkin lymphoma). Three arms:

Group A (control): R-CHOP/R-DHAP chemotherapy + autologous stem-cell transplantation (ASCT), n=288
Group A+I: same chemotherapy + ibrutinib (Bruton tyrosine kinase inhibitor) + ASCT + 2-year ibrutinib maintenance, n=292
Group I: same chemotherapy + ibrutinib, no ASCT + 2-year ibrutinib maintenance, n=290

Median follow-up: 54.9 months (~4.5 years). NCT02858258. Funded by Janssen. 4

Key findings

Failure-free survival (FFS): Adding ASCT to ibrutinib did not improve FFS vs. ibrutinib alone. 4-year FFS: A+I 82% vs. I 81% (HR 0.86, one-sided P=0.21 — not significant).

Overall survival: Both ibrutinib arms improved overall survival vs. transplant-only control. 4-year OS: A+I 88%, I 90%, A 81%. HR vs. A: 0.59 (P=0.0036) for A+I and 0.57 (P=0.0019) for I.

Toxicity: Grade 3–5 hematological adverse events during maintenance/follow-up — A+I 54%, I 28%, A 23%. Grade 3–5 infections — A+I 34%, I 26%, A 15%. Fatal adverse events: A+I 2%, I 2%.

Clinical implication

ASCT can be omitted from first-line treatment for younger MCL patients when ibrutinib is incorporated — the transplant adds substantial toxicity (54% grade 3–5 hematological events in the A+I arm) without improving failure-free survival. Ibrutinib + R-CHOP/R-DHAP induction followed by 2-year ibrutinib maintenance is now the proposed standard of care. This is a substantive practice change for a disease that has historically required transplant as consolidation.

Lead author: Martin Dreyling — LMU University Hospital, Munich, Germany

Funding: Janssen (industry)

5. Tirzepatide dose maintenance vs. reduction vs. discontinuation (SURMOUNT-MAINTAIN)

Journal: The Lancet, published online ahead of print (May 12, 2026) Impact tier: IF ~169 · First quartile Citation momentum: 1 citation; presented at ECO (European Congress on Obesity) 2026 Peer-review status: Published online in peer-reviewed journal (The Lancet); Phase 3b RCT

Study design

Phase 3b, two-period, 112-week trial at 20 US sites. Period 1 (weeks 0–60): open-label weight-loss phase in which all participants received tirzepatide titrated to their maximum tolerated dose (MTD, either 10 mg or 15 mg weekly). Period 2 (weeks 60–112): double-blind maintenance phase — 378 participants who completed period 1 were randomized to continue at MTD, reduce to 5 mg/week, or switch to placebo.

Tirzepatide (Eli Lilly) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist approved for obesity and type 2 diabetes. Baseline at randomization: mean bodyweight 113.8 kg (SD 27.0), mean BMI 40.1 kg/m², mean age 46.6 years; 65% female, 67% White. NCT06047548. 5

Key findings

Primary endpoint — percentage bodyweight change from baseline to week 112 (modified treatment-regimen estimand):

Arm	Weight change from baseline	ETD vs. placebo (95% CI)	P-value
Tirzepatide MTD	−21.9%	−12.0%	<0.0001
Tirzepatide 5 mg	−16.6%	−6.6%	<0.0001
Placebo (discontinued)	−9.9%	—	—

Rescue therapy needed (≥50% weight regain): 8% (MTD), 25% (5 mg), 67% (placebo). GI adverse effects were mostly mild-to-moderate and occurred primarily during dose escalation in period 1.

Clinical implication

The dose-response gradient is steep and clinically meaningful: patients who stopped tirzepatide regained roughly two-thirds of their lost weight within 52 weeks. Those who reduced to 5 mg maintained more weight loss than those who stopped, but substantially less than those who continued at MTD. The practical message for prescribers managing long-term obesity treatment is that discontinuation typically reverses most of the benefit, and dose reduction is a partial rather than equivalent substitute for continuation. This is the first trial to cleanly separate these three scenarios with a randomized design.

Lead author: Deborah B. Horn — University of Texas McGovern Medical School, Houston, TX Corresponding author: Clare J. Lee — Eli Lilly, Indianapolis, IN

Funding: Eli Lilly (industry)

Other notable papers indexed this week

Three additional papers from the May 14–17 window warrant a brief flag, though they did not rank in the top 5 on citation momentum and impact factor criteria:

PCOS renamed to PMOS (The Lancet, May 12): A global consensus process involving 56 organizations and 14,360 respondents adopted a new name — polyendocrine metabolic ovarian syndrome (PMOS) — replacing "polycystic ovary syndrome." The change removes inaccurate "cyst" terminology and better reflects the condition's endocrine and metabolic pathophysiology. PMOS affects approximately 1 in 8 women globally. The implementation strategy and transition timeline are ongoing. 6

FAST-Forward 10-year breast radiotherapy data (Lancet Oncology, May 14, open access): The FAST-Forward Phase 3 trial (N=4,087; 97 UK sites) confirms that 26 Gy in 5 fractions over 1 week is non-inferior to the standard 3-week regimen at 10 years. Ten-year ipsilateral breast recurrence: 2.1% (26 Gy/5 fractions) vs. 3.6% (40 Gy/15 fractions); moderate/marked late effects 14.4% vs. 13.1%. The 10-year dataset provides the long-term safety evidence needed for guideline adoption of the 1-week schedule. Funded by UK NIHR. 7

3-month vs. 12-month DAPT after CABG (BMJ, May 12): Non-inferiority RCT at 13 cardiac surgery centers in China (N=2,290 mITT). Three months of dual antiplatelet therapy (ticagrelor 90 mg twice daily + aspirin 100 mg daily) was non-inferior to 12 months for saphenous vein graft occlusion at 1 year (10.8% vs. 11.2%; absolute difference −0.31%, 95% CI −3.13% to 2.52%, P=0.008 for non-inferiority) and significantly reduced BARC type 2/3/5 bleeding (8.3% vs. 13.2%; NNT=21 to prevent one bleeding event). 8

Five papers that should be on your radar — May 17, 2026

1. Brepocitinib in dermatomyositis (VALOR) — first oral TYK2-JAK1 inhibitor clears Phase 3

Study design

Key findings

Clinical implication

2. Endovascular thrombectomy for medium-vessel-occlusion stroke (ORIENTAL-MeVO)

Study design

Key findings

Clinical implication

3. Cefepime-nacubactam for complicated UTI (Integral-1) — superior to imipenem-cilastatin

Study design

Key findings

Clinical implication

4. Ibrutinib without transplant for younger MCL patients (TRIANGLE, 4.5-year follow-up)

Study design

Key findings

Clinical implication

5. Tirzepatide dose maintenance vs. reduction vs. discontinuation (SURMOUNT-MAINTAIN)

Study design

Key findings

Clinical implication

Other notable papers indexed this week

参考ソース